Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Income from Continuing Operations (2018 - 2019)

Historic Income from Continuing Operations for DiaMedica Therapeutics (DMAC) over the last 2 years, with Q4 2019 value amounting to -$2.5 million.

  • DiaMedica Therapeutics' Income from Continuing Operations fell 2640.16% to -$2.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$10.6 million, marking a year-over-year decrease of 8571.68%. This contributed to the annual value of -$24.4 million for FY2024, which is 2612.35% down from last year.
  • Per DiaMedica Therapeutics' latest filing, its Income from Continuing Operations stood at -$2.5 million for Q4 2019, which was down 2640.16% from -$2.4 million recorded in Q3 2019.
  • In the past 5 years, DiaMedica Therapeutics' Income from Continuing Operations ranged from a high of -$650000.0 in Q1 2018 and a low of -$3.3 million during Q1 2019